Cargando…

Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease

T-cells specifically bind antigens to induce adaptive immune responses using highly specific molecular recognition, and a diverse T-cell repertoire with expansion of antigen-specific clones can indicate robust immune responses after infection or vaccination. For patients with inflammatory bowel dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Alexander M., Li, Dalin, Ebinger, Joseph E., Mengesha, Emebet, Elyanow, Rebecca, Gittelman, Rachel M., Chapman, Heidi, Joung, Sandy, Botwin, Gregory J., Pozdnyakova, Valeriya, Debbas, Philip, Mujukian, Angela, Prostko, John C., Frias, Edwin C., Stewart, James L., Horizon, Arash A., Merin, Noah, Sobhani, Kimia, Figueiredo, Jane C., Cheng, Susan, Kaplan, Ian M., McGovern, Dermot P. B., Merchant, Akil, Melmed, Gil Y., Braun, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024211/
https://www.ncbi.nlm.nih.gov/pubmed/35464463
http://dx.doi.org/10.3389/fimmu.2022.880190
_version_ 1784690523028586496
author Xu, Alexander M.
Li, Dalin
Ebinger, Joseph E.
Mengesha, Emebet
Elyanow, Rebecca
Gittelman, Rachel M.
Chapman, Heidi
Joung, Sandy
Botwin, Gregory J.
Pozdnyakova, Valeriya
Debbas, Philip
Mujukian, Angela
Prostko, John C.
Frias, Edwin C.
Stewart, James L.
Horizon, Arash A.
Merin, Noah
Sobhani, Kimia
Figueiredo, Jane C.
Cheng, Susan
Kaplan, Ian M.
McGovern, Dermot P. B.
Merchant, Akil
Melmed, Gil Y.
Braun, Jonathan
author_facet Xu, Alexander M.
Li, Dalin
Ebinger, Joseph E.
Mengesha, Emebet
Elyanow, Rebecca
Gittelman, Rachel M.
Chapman, Heidi
Joung, Sandy
Botwin, Gregory J.
Pozdnyakova, Valeriya
Debbas, Philip
Mujukian, Angela
Prostko, John C.
Frias, Edwin C.
Stewart, James L.
Horizon, Arash A.
Merin, Noah
Sobhani, Kimia
Figueiredo, Jane C.
Cheng, Susan
Kaplan, Ian M.
McGovern, Dermot P. B.
Merchant, Akil
Melmed, Gil Y.
Braun, Jonathan
author_sort Xu, Alexander M.
collection PubMed
description T-cells specifically bind antigens to induce adaptive immune responses using highly specific molecular recognition, and a diverse T-cell repertoire with expansion of antigen-specific clones can indicate robust immune responses after infection or vaccination. For patients with inflammatory bowel disease (IBD), a spectrum of chronic intestinal inflammatory diseases usually requiring immunomodulatory treatment, the T-cell response has not been well characterized. Understanding the patient factors that result in strong vaccination responses is critical to guiding vaccination schedules and identifying mechanisms of T-cell responses in IBD and other immune-mediated conditions. Here we used T-cell receptor sequencing to show that T-cell responses in an IBD cohort were influenced by demographic and immune factors, relative to a control cohort of health care workers (HCWs). Subjects were sampled at the time of SARS-CoV-2 vaccination, and longitudinally afterwards; TCR Vβ gene repertoires were sequenced and analyzed for COVID-19-specific clones. We observed significant differences in the overall strength of the T-cell response by age and vaccine type. We further stratified the T-cell response into Class-I- and Class-II-specific responses, showing that Ad26.COV2.S vector vaccine induced Class-I-biased T-cell responses, whereas mRNA vaccine types led to different responses, with mRNA-1273 vaccine inducing a more Class-I-deficient T-cell response compared to BNT162b2. Finally, we showed that these T-cell patterns were consistent with antibody levels from the same patients. Our results account for the surprising success of vaccination in nominally immuno-compromised IBD patients, while suggesting that a subset of IBD patients prone to deficiencies in T-cell response may warrant enhanced booster protocols.
format Online
Article
Text
id pubmed-9024211
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90242112022-04-23 Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease Xu, Alexander M. Li, Dalin Ebinger, Joseph E. Mengesha, Emebet Elyanow, Rebecca Gittelman, Rachel M. Chapman, Heidi Joung, Sandy Botwin, Gregory J. Pozdnyakova, Valeriya Debbas, Philip Mujukian, Angela Prostko, John C. Frias, Edwin C. Stewart, James L. Horizon, Arash A. Merin, Noah Sobhani, Kimia Figueiredo, Jane C. Cheng, Susan Kaplan, Ian M. McGovern, Dermot P. B. Merchant, Akil Melmed, Gil Y. Braun, Jonathan Front Immunol Immunology T-cells specifically bind antigens to induce adaptive immune responses using highly specific molecular recognition, and a diverse T-cell repertoire with expansion of antigen-specific clones can indicate robust immune responses after infection or vaccination. For patients with inflammatory bowel disease (IBD), a spectrum of chronic intestinal inflammatory diseases usually requiring immunomodulatory treatment, the T-cell response has not been well characterized. Understanding the patient factors that result in strong vaccination responses is critical to guiding vaccination schedules and identifying mechanisms of T-cell responses in IBD and other immune-mediated conditions. Here we used T-cell receptor sequencing to show that T-cell responses in an IBD cohort were influenced by demographic and immune factors, relative to a control cohort of health care workers (HCWs). Subjects were sampled at the time of SARS-CoV-2 vaccination, and longitudinally afterwards; TCR Vβ gene repertoires were sequenced and analyzed for COVID-19-specific clones. We observed significant differences in the overall strength of the T-cell response by age and vaccine type. We further stratified the T-cell response into Class-I- and Class-II-specific responses, showing that Ad26.COV2.S vector vaccine induced Class-I-biased T-cell responses, whereas mRNA vaccine types led to different responses, with mRNA-1273 vaccine inducing a more Class-I-deficient T-cell response compared to BNT162b2. Finally, we showed that these T-cell patterns were consistent with antibody levels from the same patients. Our results account for the surprising success of vaccination in nominally immuno-compromised IBD patients, while suggesting that a subset of IBD patients prone to deficiencies in T-cell response may warrant enhanced booster protocols. Frontiers Media S.A. 2022-04-08 /pmc/articles/PMC9024211/ /pubmed/35464463 http://dx.doi.org/10.3389/fimmu.2022.880190 Text en Copyright © 2022 Xu, Li, Ebinger, Mengesha, Elyanow, Gittelman, Chapman, Joung, Botwin, Pozdnyakova, Debbas, Mujukian, Prostko, Frias, Stewart, Horizon, Merin, Sobhani, Figueiredo, Cheng, Kaplan, McGovern, Merchant, Melmed and Braun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Xu, Alexander M.
Li, Dalin
Ebinger, Joseph E.
Mengesha, Emebet
Elyanow, Rebecca
Gittelman, Rachel M.
Chapman, Heidi
Joung, Sandy
Botwin, Gregory J.
Pozdnyakova, Valeriya
Debbas, Philip
Mujukian, Angela
Prostko, John C.
Frias, Edwin C.
Stewart, James L.
Horizon, Arash A.
Merin, Noah
Sobhani, Kimia
Figueiredo, Jane C.
Cheng, Susan
Kaplan, Ian M.
McGovern, Dermot P. B.
Merchant, Akil
Melmed, Gil Y.
Braun, Jonathan
Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease
title Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease
title_full Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease
title_fullStr Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease
title_full_unstemmed Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease
title_short Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease
title_sort differences in sars-cov-2 vaccine response dynamics between class-i- and class-ii-specific t-cell receptors in inflammatory bowel disease
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024211/
https://www.ncbi.nlm.nih.gov/pubmed/35464463
http://dx.doi.org/10.3389/fimmu.2022.880190
work_keys_str_mv AT xualexanderm differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT lidalin differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT ebingerjosephe differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT mengeshaemebet differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT elyanowrebecca differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT gittelmanrachelm differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT chapmanheidi differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT joungsandy differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT botwingregoryj differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT pozdnyakovavaleriya differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT debbasphilip differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT mujukianangela differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT prostkojohnc differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT friasedwinc differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT stewartjamesl differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT horizonarasha differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT merinnoah differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT sobhanikimia differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT figueiredojanec differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT chengsusan differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT kaplanianm differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT mcgoverndermotpb differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT merchantakil differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT melmedgily differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease
AT braunjonathan differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease